Norway Non Invasive Prenatal Testing Market Size & Outlook
- Clinical Diagnostics
- Genetic Testing
- Non Invasive Prenatal Testing Market Outlook
- Genetic Testing
Global Market
Related Markets
Ask a question about the non invasive prenatal testing market
Norway non invasive prenatal testing market highlights
- The Norway non invasive prenatal testing market generated a revenue of USD 10.8 million in 2023 and is expected to reach USD 21.6 million by 2030.
- The Norway market is expected to grow at a CAGR of 10.6% from 2024 to 2030.
- In terms of segment, 13-24 weeks was the largest revenue generating gestation period in 2023.
- 0-12 weeks is the most lucrative gestation period segment registering the fastest growth during the forecast period.
Non invasive prenatal testing market data book summary
| Market revenue in 2023 | USD 10.8 million |
| Market revenue in 2030 | USD 21.6 million |
| Growth rate | 10.6% (CAGR from 2024 to 2030) |
| Largest segment | 13-24 weeks |
| Fastest growing segment | 0-12 weeks |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
| Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global non invasive prenatal testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany non invasive prenatal testing market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 489.8 million by 2030.
Continuous developments by companies operating in the market are contributing to the country’s growth. In June 2020, NIPT was made permissible for all pregnant women in Norway, owing to changes in the Biotechnology Act passed by the Norwegian Parliament.
It further means that all pregnant women who want to know if their fetus does have certain chromosome abnormalities will shortly be able to do so in Norway rather than traveling to Sweden or Denmark, which many have done in earlier years. Thus, it will increase the demand for NIPTs and further fuel the market.
As sequencing is used more frequently in clinical settings in Norway, practical and ethical concerns are emerging around the creation of Informed Consent (IC) documents and their processes. To build a suitable IC process for testing in the clinical setting, it is difficult to bridge the gap between Norwegian legislation and regulations and clinical practice.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non Invasive Prenatal Testing Market Scope
Non Invasive Prenatal Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Natera Inc | View profile | 3,293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | www.natera.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Centogene NV Ordinary Shares | View profile | 493 | Am Strande 7, Rostock, MV, Germany, 18055 | www.centogene.com |
| Biora Therapeutics | View profile | 51-100 | Carlsbad, California, United States, North America | www.bioratherapeutics.com/ |
Norway Non Invasive Prenatal Testing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Non Invasive Prenatal Testing Market Outlook will help companies and investors design strategic landscapes.
13-24 Weeks was the largest segment with a revenue share of 57.41% in 2023.
Horizon Databook has segmented the Norway non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous developments by companies operating in the market are contributing to the country’s growth. In June 2020, NIPT was made permissible for all pregnant women in Norway, owing to changes in the Biotechnology Act passed by the Norwegian Parliament.
It further means that all pregnant women who want to know if their fetus does have certain chromosome abnormalities will shortly be able to do so in Norway rather than traveling to Sweden or Denmark, which many have done in earlier years. Thus, it will increase the demand for NIPTs and further fuel the market.
As sequencing is used more frequently in clinical settings in Norway, practical and ethical concerns are emerging around the creation of Informed Consent (IC) documents and their processes. To build a suitable IC process for testing in the clinical setting, it is difficult to bridge the gap between Norwegian legislation and regulations and clinical practice.
- Norway Non Invasive Prenatal Testing Market Gestation Period Outlook (Revenue, USD Million , 2018-2030)
- 0-12 weeks
- 13-24 weeks
- 25-36 weeks
- Norway Non Invasive Prenatal Testing Market Risk Outlook (Revenue, USD Million , 2018-2030)
- High & Average Risk
- Low Risk
- Norway Non Invasive Prenatal Testing Market Method Outlook (Revenue, USD Million , 2018-2030)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Norway Non Invasive Prenatal Testing Market Technology Outlook (Revenue, USD Million , 2018-2030)
- NGS
- Array Technology
- PCR
- Others
- Norway Non Invasive Prenatal Testing Market Product Outlook (Revenue, USD Million , 2018-2030)
- Consumables & Reagents
- Instruments
- Norway Non Invasive Prenatal Testing Market Application Outlook (Revenue, USD Million , 2018-2030)
- Trisomy
- Microdeletion Syndrome
- Other Applications
- Norway Non Invasive Prenatal Testing Market End-use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Clinics
- Diagnostic Laboratories
Reasons to subscribe to Non Invasive Prenatal Testing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Non Invasive Prenatal Testing Market Outlook databook
- Our clientele includes a mix of Non Invasive Prenatal Testing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Non Invasive Prenatal Testing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Non Invasive Prenatal Testing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Norway Non Invasive Prenatal Testing Market, 2018-2030 (US$M)
Norway non invasive prenatal testing market statistics, by gestation period, 2018-2030 (US$M)
